Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Slides:

Advertisements

Similar presentations

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

Advertisements

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Siddharth Sheth, Abuzar Moradi Tuchayi, Roy E Smith

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

by David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, R

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

TCR-MHC-peptide(s): in vivo veritas

by Enli Liu, Melanie J. Percy, Christopher I

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

How I treat elderly patients with myeloma

Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Nonmyeloablative conditioning for relapsed follicular lymphoma

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

V617F “JAKs” up myeloproliferative signal

Darwinian evolution and tiding clones in multiple myeloma

Mutagenic potential of temozolomide in bone marrow cells in vivo

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Genetic sequence analysis of inherited bleeding diseases

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Mutation Analysis of the Rearranged Immunoglobulin Heavy Chain Genes of Marginal Zone Cell Lymphomas Indicates an Origin From Different Marginal Zone B.

Evolution of extended-spectrum β-lactamases by mutation

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

by Alexander Röth, Andreas Hüttmann, Russell P

by Ernest Beutler Blood Volume 98(9): November 1, 2001

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Epigenetic heterogeneity is associated with genetic heterogeneity in CLL samples. Epigenetic heterogeneity is associated with genetic heterogeneity in.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Kenshi Hayashi et al. JACEP 2016;2:

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Role of primacy of birth in HLA-identical sibling transplantation

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

Pathogenesis of myeloproliferative neoplasms

by Alex Aleshin, and Peter L. Greenberg

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms Janine Prick, Gerald de Haan, Anthony R. Green,

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Overcoming “aspirin resistance” in MPN

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

by Elisa Rumi, and Mario Cazzola

Impact of age on clinical risk scores in follicular lymphoma

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

The NCI Genomic Data Commons as an engine for precision medicine

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

How I treat T-cell acute lymphoblastic leukemia in adults

Cold agglutinin disease

Presentation transcript:

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser, Hui Hao-Shen, Ina Nissen, Sabine Girsberger, Thomas Lehmann, Jakob Passweg, Martin Stern, Christian Beisel, Robert Kralovics, and Radek C. Skoda Blood Volume 123(14): April 3, 2014 ©2014 by American Society of Hematology

Targeted NGS in MPN: study design and workflow. Pontus Lundberg et al. Blood 2014;123: ©2014 by American Society of Hematology

Frequency and distribution of mutations in patients with MPN. (A) Number of patients with mutations in the genes is indicated. Pontus Lundberg et al. Blood 2014;123: ©2014 by American Society of Hematology

Analysis of sequential samples: clinical correlations and risk stratification. Pontus Lundberg et al. Blood 2014;123: ©2014 by American Society of Hematology

Clonal evolution in MPN patients carrying somatic mutations in epigenetic modifier genes. Pontus Lundberg et al. Blood 2014;123: ©2014 by American Society of Hematology

Model of MPN disease evolution and risk stratification in correlation to mutational events. Pontus Lundberg et al. Blood 2014;123: ©2014 by American Society of Hematology